Arteriovenous Access Outcomes and Risk of Major Cardiovascular Events in Patients with Reduced Ejection Fraction: A

Nehal Naseer1, Nadeem Ahmed Siddiqui1, Fareed Ahmed Shaikh1

  • 1Section of Vascular Surgery, Aga Khan University Hospital, Karachi, Pakistan.

Insights

Ejection fraction did not significantly affect arteriovenous fistula patency in end-stage renal disease patients. However, normal ejection fraction was linked to higher major adverse cardiovascular events, suggesting complex interactions needing more study.

Area of Science:

  • Nephrology
  • Cardiology
  • Vascular Surgery

Background:

  • End-stage renal disease (ESRD) necessitates vascular access for hemodialysis.
  • Arteriovenous fistula (AVF) is the preferred access, but maturation and patency can be affected by patient comorbidities.
  • Ejection fraction (EF), a measure of heart function, is a key comorbidity in ESRD patients.

Purpose of the Study:

  • To investigate the relationship between preoperative ejection fraction and AVF maturation and patency in ESRD patients.
  • To determine the incidence of major adverse cardiovascular events (MACE) following AVF creation in relation to EF.

Main Methods:

  • Retrospective cohort study of 127 ESRD patients undergoing AVF creation (January 2015 - December 2020).
  • Patients categorized into normal EF (Group A) and abnormal EF (Group B) based on American College of Cardiology guidelines.
  • Analysis of demographics, procedural data, AVF patency, and MACE within one year post-surgery.

Main Results:

  • AVF patency rates were comparable between normal EF (81.5%) and abnormal EF (88.6%) groups.
  • Major adverse cardiovascular events were significantly higher in the normal EF group (39.1%) compared to the abnormal EF group (12.6%).
  • Stroke occurred only in the normal EF group (6.5%); non-ST elevation myocardial infarction was the most frequent cardiac event in both groups.

Conclusions:

  • Preoperative ejection fraction did not significantly impact AVF patency in ESRD patients.
  • A trend towards lower patency was observed with increasing EF dysfunction.
  • The elevated MACE risk in normal EF patients highlights a complex interplay of factors requiring further investigation.
Abstract

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Return01:04

Venous Return

The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system as it...